Literature DB >> 26085572

Bee venom suppresses testosterone-induced benign prostatic hyperplasia by regulating the inflammatory response and apoptosis.

Kyung-Sook Chung1, Hyo-Jin An1, Se-Yun Cheon1, Ki-Rok Kwon2, Kwang-Ho Lee3.   

Abstract

Benign prostatic hyperplasia (BPH), which is a common disorder in aging men, involves inflammation that is associated with an imbalance between cell proliferation and cell death. Because current BPH drug treatments have undesirable side effects, the development of well-tolerated and effective alternative medicines to treat BPH is of interest. Bee venom (BV) has been used in traditional medicine to treat conditions, such as arthritis and rheumatism, and pain. Although inflammation has been associated with BPH and BV has strong anti-inflammatory effects, the effects of BV on BPH are not fully understood. Therefore, in this study, we evaluated the efficacy of BV against testosterone-induced BPH in rats. BV decreased prostate weight compared to the untreated group. In addition, BV suppressed serum dihydrotestosterone concentration levels and the levels of proliferating cell nuclear antigen in the histological analysis. Furthermore, BV significantly decreased the levels of the apoptotic suppressors, Bcl-2 and Bcl-xL, and increased the levels of the proapoptotic factors, Bax and caspase-3 activation. These results suggested that BV suppressed the development of BPH and has good potential as a treatment for BPH.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Bcl-2/Bax ratio; Bee venom; Benign prostatic hyperplasia; apoptosis; caspase; inflammation

Mesh:

Substances:

Year:  2015        PMID: 26085572      PMCID: PMC4935329          DOI: 10.1177/1535370215590823

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  24 in total

Review 1.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

2.  Role of inflammation in benign prostatic hyperplasia.

Authors:  Bilal Chughtai; Richard Lee; Alexis Te; Steven Kaplan
Journal:  Rev Urol       Date:  2011

3.  Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.

Authors:  Mi Hee Park; Myoung Suk Choi; Dong Hoon Kwak; Ki-Wan Oh; Do Young Yoon; Sang Bae Han; Ho Sueb Song; Min Jong Song; Jin Tae Hong
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

4.  Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Authors:  Franco Di Silverio; Cesare Bosman; Monti Salvatori; Luca Albanesi; Laura Proietti Pannunzi; Mauro Ciccariello; Antonio Cardi; Gianfilippo Salvatori; Alessandro Sciarra
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

5.  Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma.

Authors:  S Baltaci; D Orhan; C Gögüs; K Türkölmez; O Tulunay ; O Gögüs
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

6.  Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies.

Authors:  Pamela J Russell; Dean Hewish; Teresa Carter; Katy Sterling-Levis; Kim Ow; Meghan Hattarki; Larissa Doughty; Robin Guthrie; Deborah Shapira; Peter L Molloy; Jerome A Werkmeister; Alexander A Kortt
Journal:  Cancer Immunol Immunother       Date:  2004-01-13       Impact factor: 6.968

Review 7.  5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Authors:  Roger S Rittmaster
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

8.  Reperfusion differentially induces caspase-3 activation in ischemic core and penumbra after stroke in immature brain.

Authors:  C Manabat; B H Han; M Wendland; N Derugin; C K Fox; J Choi; D M Holtzman; D M Ferriero; Z S Vexler
Journal:  Stroke       Date:  2003-01       Impact factor: 7.914

9.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

Review 10.  The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer.

Authors:  Johny E Elkahwaji
Journal:  Res Rep Urol       Date:  2012-12-31
View more
  6 in total

1.  Bee Venom Suppresses the Differentiation of Preadipocytes and High Fat Diet-Induced Obesity by Inhibiting Adipogenesis.

Authors:  Se-Yun Cheon; Kyung-Sook Chung; Seong-Soo Roh; Yun-Yeop Cha; Hyo-Jin An
Journal:  Toxins (Basel)       Date:  2017-12-24       Impact factor: 4.546

2.  Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study.

Authors:  Giuseppe Morgia; Antonio Micali; Mariagrazia Rinaldi; Natasha Irrera; Herbert Marini; Domenico Puzzolo; Antonina Pisani; Salvatore Privitera; Giorgio I Russo; Sebastiano Cimino; Antonio Ieni; Vincenzo Trichilo; Domenica Altavilla; Francesco Squadrito; Letteria Minutoli
Journal:  Int J Mol Sci       Date:  2017-03-22       Impact factor: 5.923

3.  Rhodobacter sphaeroides Extract Lycogen™ Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats.

Authors:  Chiang-Ting Wang; Ya-Yun Wang; Wen-Sheng Liu; Chun-Ming Cheng; Kuo-Hsun Chiu; Li-Lian Liu; Xue-Zhu Liu; Zhi-Hong Wen; Ya-Huey Chen; Tsung-Ming Chen
Journal:  Int J Mol Sci       Date:  2018-04-10       Impact factor: 5.923

4.  The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats.

Authors:  Hongcai Cai; Guowei Zhang; Zechen Yan; Xuejun Shang
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-30       Impact factor: 2.629

5.  Clinical Applications of Bee Venom Acupoint Injection.

Authors:  Ting-Yen Lin; Ching-Liang Hsieh
Journal:  Toxins (Basel)       Date:  2020-09-27       Impact factor: 4.546

Review 6.  Bee Venom Components as Therapeutic Tools against Prostate Cancer.

Authors:  Jasmin Katrin Badawi
Journal:  Toxins (Basel)       Date:  2021-05-07       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.